As shared on drugs.com, Vascarta Inc. has reported encouraging results from a Phase 1b clinical study evaluating its investigational topical/transdermal curcumin gel, VAS-101, for the treatment of knee pain associated with osteoarthritis. The findings were published in the peer‑reviewed journal Frontiers in Pain Research and suggest that localized delivery of curcumin may offer a safe and effective non‑oral option for pain management in this common degenerative joint condition.
Study Overview
The randomized, double‑blind, placebo‑controlled trial enrolled 60 adults between the ages of 45 and 75 with diagnosed knee osteoarthritis. Participants were assigned to apply either VAS-101 or a placebo gel to the affected knee every other day over a 28‑day period. Each application consisted of 0.1 mL of gel.
Pain and function outcomes were measured using validated assessment tools, with the Knee injury and Osteoarthritis Outcome Score (KOOS) pain subscale serving as the primary endpoint. Secondary measures included daily self‑reported pain scores, performance‑based physical function tests, and the use of rescue oral analgesic medications.
Key Findings
Participants treated with VAS-101 experienced greater improvements in knee pain compared with those receiving placebo. The study met its primary endpoint, showing a statistically significant improvement in KOOS pain scores. Daily pain ratings also declined to a greater extent in the active treatment group.
Clinically meaningful benefits were observed in a substantial proportion of patients. Nearly 40% of individuals using VAS-101 rated their condition as “much improved” or “very much improved,” compared with just over 13% in the placebo group. In addition, approximately one‑third of treated participants achieved a minimal clinically important difference in symptoms, more than double the rate seen with placebo.
Safety and Tolerability
VAS-101 was generally well tolerated throughout the study period. No serious or treatment‑limiting adverse events were reported. A small number of participants experienced temporary skin staining at the application site, a known characteristic of topical curcumin products, which resolved within a few days after discontinuation.
Expert Commentary and Implications
According to principal investigator Dr. Adrian Lopresti, the results indicate that topical application of VAS-101 can reduce knee pain within one month of use, with meaningful benefits for a subset of patients. He noted that these findings support further investigation of VAS-101 as a potential therapeutic option for knee osteoarthritis.
Company leadership emphasized the broader implications of the study. Joel Friedman, MD, PhD, Vascarta’s Chief Scientific Officer, highlighted that topical delivery may help overcome absorption and tolerability challenges associated with oral curcumin formulations. Meanwhile, CEO Richard Prince, PhD, stated that the company plans to advance development through regulatory pathways, including a planned Investigational New Drug application to the U.S. Food and Drug Administration.
Next Steps
While larger and longer‑term studies will be needed to confirm efficacy and durability of response, this early‑phase trial provides preliminary evidence that transdermal curcumin delivery could play a role in managing osteoarthritis‑related knee pain. If validated in future trials, VAS‑101 may expand non‑systemic treatment options for patients seeking alternatives to oral analgesics or anti‑inflammatory medications.
